Fisher Asset Management LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Fisher Asset Management LLC purchased a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 100,691 shares of the company’s stock, valued at approximately $997,000. Fisher Asset Management LLC owned approximately 0.10% of Tango Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Tango Therapeutics by 421.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,793 shares of the company’s stock valued at $117,000 after acquiring an additional 9,530 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in shares of Tango Therapeutics during the third quarter valued at $144,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Tango Therapeutics by 570.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,902 shares of the company’s stock valued at $138,000 after acquiring an additional 11,829 shares in the last quarter. L2 Asset Management LLC bought a new position in shares of Tango Therapeutics during the third quarter valued at $185,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Tango Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 16,474 shares of the company’s stock valued at $163,000 after acquiring an additional 4,177 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Tango Therapeutics in a report on Thursday. Wedbush reiterated an “outperform” rating and issued a $18.00 price objective on shares of Tango Therapeutics in a report on Monday, March 18th. Piper Sandler assumed coverage on Tango Therapeutics in a report on Monday, February 12th. They issued an “overweight” rating and a $18.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on Tango Therapeutics in a report on Thursday, April 4th. They issued an “overweight” rating for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.25.

Insiders Place Their Bets

In other news, insider Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.43, for a total transaction of $557,250.00. Following the transaction, the insider now directly owns 618,524 shares of the company’s stock, valued at approximately $4,595,633.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.43, for a total transaction of $557,250.00. Following the transaction, the insider now directly owns 618,524 shares of the company’s stock, valued at approximately $4,595,633.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Rock Ventures Iv L.P. Third sold 162,500 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $12.00, for a total value of $1,950,000.00. Following the transaction, the insider now directly owns 19,201,475 shares in the company, valued at $230,417,700. The disclosure for this sale can be found here. Over the last three months, insiders have sold 297,500 shares of company stock valued at $2,963,850. Insiders own 6.20% of the company’s stock.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX opened at $7.77 on Friday. The stock has a market capitalization of $829.37 million, a price-to-earnings ratio of -7.06 and a beta of 0.84. The stock’s 50-day simple moving average is $8.30 and its two-hundred day simple moving average is $9.33. Tango Therapeutics, Inc. has a 52-week low of $2.47 and a 52-week high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Monday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The firm had revenue of $5.43 million during the quarter, compared to analysts’ expectations of $7.86 million. Tango Therapeutics had a negative return on equity of 41.96% and a negative net margin of 278.55%. As a group, equities analysts forecast that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.